Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review
Open accessThe DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Background: The proteins S100B, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and neurofilament light (NF-L) have been serially sampled in serum of patients suffering from traumatic brain injury (TBI) in order to assess injury severity and tissue fate. We review the current literature of serum level dynamics of these proteins following TBI and used the term “effective half-life” (t½) in order to describe the “fall” rate in serum Material and methods: Through searches on EMBASE, Medline and Scopus, we looked for articles where these proteins had been serially sampled in serum in human TBI. We excluded animal studies, studies with only one presented sample and studies without neuroradiological examinations. Results: Following screening (10,389 papers), n=122 papers were included. The proteins S100B (n=66) and NSE (n=27) were the two most frequent biomarkers that were serially sampled. For S100B in severe TBI, a majority of studies indicate a t½ of about 24 hours, even if very early sampling in these patients reveals rapid decreases (1-2 hours) though possibly of non-cerebral origin. In contrast, the t½ for NSE is comparably longer, ranging from 48-72 hours in severe TBI cases. The protein GFAP (n=18) appears to have t½ of about 24-48 hours in severe TBI. The protein UCH-L1 (n=9) present a t½ around 7 hours in mild TBI, and about 10 hours in severe. Frequent sampling of these proteins revealed different trajectories with persisting high serum levels, or secondary peaks, in patients with unfavorable outcome or in patients developing secondary detrimental events. Finally, NF-L (n=2) only increased in the few studies available, suggesting a serum availability >10 days. To date, automated assays are available for S100B and NSE making them faster and more practical to use. Conclusion: Serial sampling of brain specific proteins in serum reveals different temporal trajectories that should be acknowledged. Proteins with shorter serum availability, like S100B, may be superior to proteins such as NF-L in detection of secondary harmful events when monitoring patients with TBI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Communication in the presence of noise
Shannon, C. E. (1949) · Proceedings of the IRE · doi:10.1109/jrproc.1949.232969 · Cited by 6,539
Communication In The Presence Of Noise
Shannon, C. E. (1998) · Proceedings of the IEEE · doi:10.1109/jproc.1998.659497 · Cited by 4,804
Moderate and severe traumatic brain injury in adults
Maas, A. I., Stocchetti, N., & Bullock, R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70164-9 · Cited by 2,123 · cited 1×
“TBI consists of two processes: the initial traumatic impact at the scene causing primary damage to the cerebral parenchyma and blood vessels, which ca n be followed by the onset of detrimental secondary insults (4), characterized by progressive cell death due to inflammation, impaired cerebral blood flow and metabolic…”
Changing patterns in the epidemiology of traumatic brain injury
Roozenbeek, B., Maas, A. I. R., & Menon, D. K. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.22 · Cited by 1,368
Self-citationA systematic review of brain injury epidemiology in Europe
Tagliaferri, F., Compagnone, C., Korsic, M., Servadei, F., & Kraus, J. (2006) · Acta Neurochirurgica · doi:10.1007/s00701-005-0651-y · Cited by 1,223
Traumatic Brain Injury: A Disease Process, Not an Event
Masel, B. E., & DeWitt, D. S. (2010) · Journal of Neurotrauma · doi:10.1089/neu.2010.1358 · Cited by 955
Panic, N., Leoncini, E., de Belvis, G., Ricciardi, W., & Boccia, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083138 · Cited by 883 · cited 1×
“Data were reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (see Data Sheet S1 in Supplementary Material for PRISMA checklist) (32).”
Assessment and prognosis of coma after head injury
Teasdale, G., & Jennett, B. (1976) · Acta Neurochirurgica · doi:10.1007/bf01405862 · Cited by 822
S100B's double life: Intracellular regulator and extracellular signal
Donato, R., Sorci, G., Riuzzi, F., Arcuri, C., Bianchi, R., Brozzi, F., Tubaro, C., & Giambanco, I. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.11.009 · Cited by 731
Cited by
Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research
Maas, A. I. R., Menon, D. K., Adelson, P. D., Andelic, N., Bell, M. J., Belli, A., Bragge, P., Brazinova, A., Büki, A., Chesnut, R. M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30371-x · Cited by 2,609
Self-citationTraumatic brain injury: progress and challenges in prevention, clinical care, and research
Maas, A. I. R., Menon, D. K., Manley, G. T., Abrams, M., Åkerlund, C., Andelic, N., Aries, M., Bashford, T., Bell, M. J., Bodien, Y. G., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00309-x · Cited by 1,520
Self-citationBlood GFAP as an emerging biomarker in brain and spinal cord disorders
Abdelhak, A., Foschi, M., Abu-Rumeileh, S., Yue, J. K., D’Anna, L., Huss, A., Oeckl, P., Ludolph, A. C., Kuhle, J., Petzold, A., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00616-3 · Cited by 807
Recent advances in traumatic brain injury
Khellaf, A., Khan, D. Z., & Helmy, A. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09541-4 · Cited by 485
Self-citationNeurofilaments as biomarkers in neurological disorders — towards clinical application
Khalil, M., Teunissen, C. E., Lehmann, S., Otto, M., Piehl, F., Ziemssen, T., Bittner, S., Sormani, M. P., Gattringer, T., Abu-Rumeileh, S., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00955-x · Cited by 446
Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19
Kanberg, N., Ashton, N. J., Andersson, L.-M., Yilmaz, A., Lindh, M., Nilsson, S., Price, R. W., Blennow, K., Zetterberg, H., & Gisslén, M. (2020) · Neurology · doi:10.1212/wnl.0000000000010111 · Cited by 371
Neurofilaments: neurobiological foundations for biomarker applications
Gafson, A. R., Barthélemy, N. R., Bomont, P., Carare, R. O., Durham, H. D., Julien, J.-P., Kuhle, J., Leppert, D., Nixon, R. A., Weller, R. O., et al. (2020) · Brain · doi:10.1093/brain/awaa098 · Cited by 325
Hergenroeder, G. W., Moore, A. N., McCoy, J. P., Samsel, L., Ward, N. H., Clifton, G. L., & Dash, P. K. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-19 · Cited by 163
Huebschmann, N. A., Luoto, T. M., Karr, J. E., Berghem, K., Blennow, K., Zetterberg, H., Ashton, N. J., Simrén, J., Posti, J. P., Gill, J. M., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.01054 · Cited by 85
Bazarian, J. J., Zetterberg, H., Buki, A., Dengler, B. A., Diaz-Arrastia, R., Korley, F. K., Lazarus, R., Meier, T. B., Mondello, S., Moritz, K., et al. (2025) · Journal of Neurotrauma · doi:10.1089/neu.2024.0581 · Cited by 61
“66 Additionally, BBM results can in fl uence care intensity and assess situations where aggressive treat-ment might be futile.”
Self-citationExtracellular vesicles: pathogenetic, diagnostic and therapeutic value in traumatic brain injury
Mondello, S., Thelin, E. P., Shaw, G., Salzet, M., Visalli, C., Cizkova, D., Kobeissy, F., & Buki, A. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1464914 · Cited by 53
Self-citationBiomarkers in Moderate to Severe Pediatric Traumatic Brain Injury: A Review of the Literature
Munoz Pareja, J. C., Li, X., Gandham, N., Wang, K. K., Lautenslager, L., Pareja, M. C., Shanmugham, P., Faulkinberry, S., Ghosh, S., Kerrigan, M., et al. (2022) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2022.03.002 · Cited by 27
Metadata
- Authors
- Thelin, E. P., Zeiler, F. A., Ercole, A., Mondello, S., Büki, A., Bellander, B.-M., Helmy, A., Menon, D. K., & Nelson, D. W.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2017-07-03
- Volume
- 8
- Pages
- 300-300
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2725785615
- Cited by
- 260
- References
- 98
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.